Study of effect modifiers of genetically predicted CETP reduction

Competing Interest Statement

JCT reports grants from the Government of Quebec, Amarin, Esperion, Ionis, Servier, RegenXBio; personal fees from AstraZeneca, Sanofi, Servier; and personal fees and minor equity interest from Dalcor. In addition, JCT is author on a submitted patent Methods of treating a coronavirus infection using Colchicine pending, and a patent Early administration of low-dose colchicine after myocardial infarction pending. MPD and JCT have a patent Methods for Treating or Preventing Cardiovascular Disorders and Lowering Risk of Cardiovascular Events issued to Dalcor, no royalties received, a patent Genetic Markers for Predicting Responsiveness to Therapy with HDL-Raising or HDL Mimicking Agent issued to Dalcor, no royalties received, and a patent Methods for using low dose colchicine after myocardial infarction, assigned to the Montreal Heart Institute. MPD reports personal fees and other from Dalcor and personal fees from GlaxoSmithKline, other from AstraZeneca, Pfizer, Servier, Sanofi. JH has received speaker honoraria from Dalcor and District 3 Innovation Centre. Other authors have nothing to declare.

Funding Statement

The work was funded by the Canadian Institutes of Health Research (CIHR) grant #162307, the Health Collaboration Acceleration Fund from the Government of Quebec, and Genome Canada and Genome Quebec. The Montreal Heart Institute (MHI) Biobank is funded by the MHI Foundation. MAL holds a scholarship from Canadian Institutes of Health Research (CIHR); MPD holds the Canada Research Chair in Precision medicine data analysis. JCT holds the Canada Research Chair in Personalized Medicine and the Université de Montréal Pfizer-endowed research chair in atherosclerosis. JGH is an IVADO Professor and a Fonds de la Recherche en Santé (FRQS) Junior 1 fellow. IG receives a PhD scholarship from the MHI Foundation.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This project was approved by the institutional review board of the Montreal Heart Institute called “Comité d’éthique de la recherche et du développement des nouvelles technologies de l’Institut de Cardiologie de Montréal” under project number 2015-1856. All participants of the UK Biobank gave written consent and the UK Biobank has approval from the “North West Multi-centre Research Ethics Committee” (MREC).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes